Zafgen Thinks Phase III Data Could Be Key To Lifting FDA Hold
This article was originally published in The Pink Sheet Daily
Executive Summary
With Phase III data showing beloranib can result in weight loss and improvement in hyperphagia-related behavior, Zafgen hopes the candidate placed on clinical hold Dec. 2 can move back into active development.